Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results
Trinity Biotech secured purchase orders for over 2 million units of its TrinScreen HIV rapid test, scheduled for delivery in Q3 2026, which supports full-year revenue and profitability targets. Q1 2026 revenue increased 43% year-over-year to $10.8 million, driven by a $3.3 million contribution from Rapid HIV sales and growth in haemoglobin products.
Key figures
- Revenue
- 10800000
- Gross profit
- 3800000
- Orders units
- 2000000
- Gross margin percent
- 35.4%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.